Hologic Inc (HOLX) reports a 1% revenue increase with robust diagnostics performance, while facing headwinds in breast health ...

Hologic lowered its fiscal 2025 revenue forecast, citing weakness in sales of its breast health products, sending the company ...

Medical technology company Hologic (NASDAQ:HOLX) met Wall Street’s revenue expectations in Q4 CY2024, but sales were flat ...

Raymond James lowered the firm’s price target on Hologic (HOLX) to $90 from $95 and keeps an Outperform rating on the shares. Hologic’s print ...

Leerink downgraded Hologic (HOLX) to Market Perform from Outperform with a price target of $75, down from $80, following the fiscal Q1 report.

Q1 2025 Earnings Conference Call February 5, 2025 4:30 PM ETCompany ParticipantsMike Watts - Corporate Vice President, ...

Essex Mitchell; Chief Operating Officer; Hologic Inc Karleen Oberton; Chief Financial Officer; Hologic Inc Tycho Peterson; Analyst; Jeffries. Tejas Savant; Analyst; Morgan Stanley & Co. LLC Andrew ...

The company guided Q2 2025 revenues to be between $995 million and $1.005 billion, with non-GAAP EPS expected in the range of $1 to $1.03. Full-year revenue guidance was revised to $4.05 billion to $4 ...

Hologic, Inc. HOLX reported adjusted earnings per share (EPS) of $1.03 in the first quarter of fiscal 2025, up 5.1% year over year. The metric surpassed the Zacks Consensus Estimate by 0.9%. Find the ...

Fintel reports that on February 3, 2025, Needham downgraded their outlook for Hologic (NasdaqGS:HOLX) from Buy to Hold.

Hologic (NASDAQ:HOLX – Get Free Report) will likely be issuing its quarterly earnings data after the market closes on ...

Explore advancements in women's health through AI, equity, and policy with Mia Keeys of Hologic on I Don’t Care.